Optimum Platelet Inhibition After Coronary Bypass Surgery
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.
Preoperative exclusion criteria:
patients who are have not stopped aspirin 7 days prior to surgery
patients on concomitant NSAIDS
patients with a previous history platelet disorders, splenectomy or haematological disorders
patients with aspirin induced asthma
patients with any contraindications to aspirin (GI bleed)
patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
Women of childbearing potential
Patients of less than 18 years
If informed consent cannot be obtained
If for any reason the consultant surgeon or anaesthetist deems it to be appropriate